Cyclacel Pharmaceuticals (CYCCP) Stock Analysis

What Cyclacel Pharmaceuticals does

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing therapeutic solutions for cancer and various other proliferative disorders. At the forefront of its pipeline are several investigational therapies: Fadraciclib, a cyclin-dependent kinase (CDK) inhibitor, is currently undergoing Phase 1/2 clinical evaluation. It's being assessed as a monotherapy for solid tumors and in combination with venetoclax for managing relapsed or refractory chronic lymphocytic leukemia. Another promising candidate is CYC140, a polo-like kinase inhibitor, also progressing through Phase 1/2 trials for advanced leukemias and various solid tumor types. The pipeline further features Sapacitabine, an orally available prodrug of CNDAC and a novel nucleoside analog. This compound is in Phase 1/2 clinical investigation for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Additionally, seliciclib, another CDK inhibitor, is being explored in investigator-sponsored trials (ISTs), specifically in Phase 2 for Cushing's disease and Phase 1/2 for advanced rheumatoid arthritis. Underscoring its commitment to research, Cyclacel maintains a clinical collaboration with the University of Texas MD Anderson Cancer Center. This partnership aims to assess the safety and effectiveness of three of its compounds in patients suffering from various hematological malignancies, including chronic lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndromes, and other advanced forms of leukemia. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

Key metrics

ETFs linked to CYCCP

Broad-market and Healthcare sector ETFs an investor holding Cyclacel Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CYCCP fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals trades under the ticker CYCCP on NASDAQ.

Which exchange is CYCCP listed on?

CYCCP is listed on NASDAQ.

What sector does Cyclacel Pharmaceuticals operate in?

Cyclacel Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CYCCP in a portfolio?

PortView shows CYCCP's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.